A prognostic DNA methylation signature for stage I non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 31, Issue 32, 2013, Pages 4140-4147

  Sandoval, Juan ^a   Mendez Gonzalez, Jesus ^a   Nadal, Ernest ^h   Chen, Guoan ^h   Carmona, F Javier ^a   Sayols, Sergi ^a   Moran, Sebastian ^a   Heyn, Holger ^a   Vizoso, Miguel ^a   Gomez, Antonio ^a   Sanchez Cespedes, Montse ^a   Assenov, Yassen ⁱ   Müller, Fabian ⁱ   Bock, Christoph ^j   Taron, Miquel ^d   Mora, Josefina ^b   Muscarella, Lucia A ^k   Liloglou, Triantafillos ^l   Davies, Michael ^l   Pollan, Marina ^e   Pajares, Maria J ^f   Torre, Wenceslao ^g   Montuenga, Luis M ^f   Brambilla, Elisabeth ^m   Field, John K ^l   Roz, Luca ⁿ   Lo Iacono, Marco ^o   Scagliotti, Giorgio V ^o   Rosell, Rafael ^d   Beer, David G ^h   Esteller, Manel ^a,c,p   more..

^a Bellvitge Biomedical Research Institute   (United States)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f UNIVERSITY OF NAVARRA   (Spain)

^g UNIVERSITY CLINIC OF NAVARRA   (Spain)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

ⁱ MAX PLANCK INSTITUTE   (Germany)

^j ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^k CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^l UNIVERSITY OF LIVERPOOL   (United Kingdom)

^m HÔPITAL MICHALLON   (France)

ⁿ NATIONAL CANCER INSTITUTE   (Italy)

^o UNIVERSITY OF TURIN   (Italy)

^p HOSPITAL DURAN I REYNALS   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALX HOMEOBOX PROTEIN 1; ANTINEOPLASTIC AGENT; CDH 13 PROTEIN; HISTONE CLUSTER1 H4F; NEUROPEPTIDE B W RECEPTOR 1; PEPTIDES AND PROTEINS; PROTOCADHERIN GAMMA SUBFAMILY B6; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TRANSCRIPTION FACTOR HOXA9; TRANSCRIPTION FACTOR OTX2; TRIM 58 PROTEIN; UNCLASSIFIED DRUG; TRANSCRIPTOME; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL OUTCOME; COMPUTER ASSISTED TOMOGRAPHY; CPG ISLAND; DNA METHYLATION; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; LOBECTOMY; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PYROSEQUENCING; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; SEGMENTECTOMY; SEX; SMOKING; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; CLUSTER ANALYSIS; DISEASE FREE SURVIVAL; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CLUSTER ANALYSIS; CPG ISLANDS; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84891801684     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.48.5516     Document Type: Article

References (42)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62:10-29, 2012
2. Scagliotti GV, Fossati R, Torri V, et al: Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 95:1453-1461, 2003
3. Waller D, Peake MD, Stephens RJ, et al: Chemotherapy for patients with non-small cell lung cancer: The surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 26:173-182, 2004
4. Winton T, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs. observation in resected non-smallcell lung cancer. N Engl J Med 352:2589-2597, 2005
5. Douillard JY, Rosell R, De Lena M, et al: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol 7:719-727, 2006
6. Arriagada R, Dunant A, Pignon JP, et al: Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 28:35-42, 2010
7. Pignon JP, Tribodet H, Scagliotti GV, et al: Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 26:3552-3559, 2008
8. Strauss GM, Herndon JE 2nd, Maddaus MA, et al: Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26:5043-5051, 2008
9. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-2054, 2003
10. Esteller M: Epigenetics in cancer. N Engl J Med 358:1148-1159, 2008
11. Baylin SB, Jones PA: A decade of exploring the cancer epigenome: Biological and translational implications. Nat Rev Cancer 11:726-734, 2011
12. Sandoval J, Heyn H, Moran S, et al: Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics 6:692-702, 2011
13. Bibikova M, Barnes B, Tsan C, et al: High density DNA methylation array with single CpG site resolution. Genomics 98:288-295, 2011
14. National Center for Biotechnology Information: Gene Expression Omnibus. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc-GSE39279
15. Fernandez AF, Assenov Y, Martin-Subero JI, et al: A DNA methylation fingerprint of 1628 human samples. Genome Res 22:407-419, 2012
16. Travis WD, Brambilla E, Muller-Hermlink HK, et al: Pathology and genetics of tumours of the lung, pleura, thymus and heart, in, World Health Organization (eds): Classification of Tumours, Lyon, France, IARC Press, 2004
17. Curado MP, Edwards B, Shin HR, et al: Cancer Incidence in Five Continents, Vol IX. Lyon, France, International Agency for Research on Cancer (IARC) Scientific Publication 160, 2007
18. Janssen-Heijnen ML, Coebergh JW: The changing epidemiology of lung cancer in Europe. Lung Cancer 41:245-258, 2003
19. Martini N, Bains MS, Burt ME, et al: Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 109:120-129, 1995
20. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111:1710-1717, 1997
21. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 355:479-485, 2000
22. Fujisawa T, Iizasa T, Saitoh Y, et al: Smoking before surgery predicts poor long-term survival in patients with stage I non-small-cell lung carcinomas. J Clin Oncol 17:2086-2091, 1999
23. Irizarry RA, Ladd-Acosta C, Wen B, et al: The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 41:178-186, 2009
24. Hansen KD, Timp W, Bravo HC, et al: Increased methylation variation in epigenetic domains across cancer types. Nat Genet 43:768-775, 2011
25. Brock MV, Hooker CM, Ota-Machida E, et al:DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358:1118-1128, 2008
26. Cancer Genome Atlas Research Network: Comprehensive genomic characterization of squamous cell lung cancers. Nature 489:519-525, 2012
27. Kratz JR, He J, Van Den Eeden SK, et al: A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: Development and international validation studies. Lancet 379:823-832, 2012
28. Brena RM, Morrison C, Liyanarachchi S, et al: Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung cancer. PLoS Med 4:e108, 2007
29. Rauch T, Wang Z, Zhang X, et al: Homeobox gene methylation in lung cancer studied by genomewide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci U S A 104:5527-5532, 2007
30. Christensen BC, Marsit CJ, Houseman EA, et al: Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles. Cancer Res 69: 6315-6321, 2009
31. Selamat SA, Chung BS, Girard L, et al: Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res 22:1197-1211, 2012
32. Heller G, Babinsky VN, Ziegler B, et al: Genome-wide CpG island methylation analyses in non-small cell lung cancer patients. Carcinogenesis 34:513-521, 2013
33. Toyooka S, Suzuki M, Maruyama R, et al: The relationship between aberrant methylation and survival in non-small-cell lung cancers. Br J Cancer 91:771-774, 2004
34. Claus R, Lucas DM, Stilgenbauer S, et al: Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol 30:2483-2491, 2012
35. Son JW, Jeong KJ, Jean WS, et al: Genome-wide combination profiling of DNA copy number and methylation for deciphering biomarkers in non-small cell lung cancer patients. Cancer Lett 311:29-37, 2011
36. Nelson HH, Marsit CJ, Christensen BC, et al: Key epigenetic changes associated with lung cancer development: Results from dense methylation array profiling. Epigenetics 7:559-566, 2012
37. Alaminos M, Davalos V, Cheung NK, et al: Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst 96:1208-1219, 2004
38. Di Vinci A, Casciano I, Marasco E, et al: Quantitative methylation analysis of HOXA3, 7, 9, and 10 genes in glioma: Association with tumor WHO grade and clinical outcome. J Cancer Res Clin Oncol 138:35-47, 2012
39. Miyamoto K, Fukutomi T, Akashi-Tanaka S, et al: Identification of 20 genes aberrantly methylated in human breast cancers. Int J Cancer 116:407-414, 2005
40. Cottrell S, Jung K, Kristiansen G, et al: Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J Urol 177:1753-1758, 2007
41. Ramalingam SS, Maitland ML, Frankel P, et al: Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 28:56-62, 2010
42. Juergens RA, Wrangle J, Vendetti FP, et al: Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 1:598-607, 2011